<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Meningococcal vaccination recommendations for persons age ≥2 years who are at increased risk of meningococcal disease in the United States&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Meningococcal vaccination recommendations for persons age ≥2 years who are at increased risk of meningococcal disease in the United States<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Meningococcal vaccination recommendations for persons age ≥2 years who are at increased risk of meningococcal disease in the United States<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Risk factor</td> <td class="subtitle1" colspan="2">MenACWY</td> <td class="subtitle1" colspan="2">MenB for those ≥10 years of age</td> </tr> <tr> <td class="subtitle2">Primary dose(s)</td> <td class="subtitle2">Booster dose(s) if increased risk persists</td> <td class="subtitle2">Primary dose(s)</td> <td class="subtitle2">Booster dose(s) if increased risk persists</td> </tr> <tr> <td colspan="5"><strong>Immunodeficiency that increases the risk of meningococcal disease</strong></td> </tr> <tr> <td class="indent1">Complement component deficiency (eg, C3, C5-C9, properdin, factor H, factor D) or use of complement inhibitors (eg, eculizumab, ravulizumab)*</td> <td>2 doses of any MenACWY, ≥8 weeks apart</td> <td> <ul> <li>Age &lt;7 years: 3 years after completion of primary series and every 5 years thereafter</li> <li>Age ≥7 years: every 5 years</li> </ul> </td> <td> Either: <ul class="decimal_heading"> <li>MenB-4C: 2 doses, ≥4 weeks apart</li> <li style="list-style-type: none;"><strong>or</strong></li> <li>MenB-FHbp: 3 doses on a 0-, 1- to 2-, and 6-month schedule</li> </ul> </td> <td>1 year after completion of primary series and every 2 to 3 years thereafter.</td> </tr> <tr> <td class="indent1">Anatomic or functional asplenia including sickle cell disease</td> <td>2 doses of any MenACWY, ≥8 weeks apart</td> <td> <ul> <li>Age &lt;7 years: 3 years after completion of primary series and every 5 years thereafter</li> <li>Age ≥7 years: every 5 years</li> </ul> </td> <td> Either: <ul class="decimal_heading"> <li>MenB-4C: 2 doses, ≥4 weeks apart</li> <li style="list-style-type: none;"><strong>or</strong></li> <li>MenB-FHbp: 3 doses on a 0-, 1- to 2-, and 6-month schedule</li> </ul> </td> <td>1 year after completion of primary series and every 2 to 3 years thereafter.</td> </tr> <tr> <td class="indent1">Persons with HIV</td> <td>2 doses of any MenACWY, ≥8 weeks apart</td> <td> <ul> <li>Age &lt;7 years: 3 years after completion of primary series and every 5 years thereafter</li> <li>Age ≥7 years: every 5 years</li> </ul> </td> <td colspan="2">MenB is not recommended unless it is otherwise indicated (eg, age 16 through 23 years based on shared decision-making).</td> </tr> <tr> <td colspan="5"><strong>Increased risk of exposure to meningococcal disease</strong></td> </tr> <tr> <td class="indent1">Microbiologists routinely exposed to meningococcus</td> <td>1 dose of any MenACWY<sup>¶</sup></td> <td> <ul> <li>Every 5 years</li> </ul> </td> <td> Either: <ul class="decimal_heading"> <li>MenB-4C: 2 doses, ≥4 weeks apart</li> <li style="list-style-type: none;"><strong>or</strong></li> <li>MenB-FHbp: 3 doses on a 0-, 1- to 2-, and 6-month schedule</li> </ul> </td> <td>1 year after completion of primary series and every 2 to 3 years thereafter.</td> </tr> <tr> <td class="indent1">Persons who travel to or are residents of countries where meningococcal disease is hyperendemic or epidemic<sup>Δ</sup></td> <td>1 dose of any MenACWY<sup>¶</sup></td> <td> <ul> <li>Age &lt;7 years: 3 years after completion of primary series and every 5 years thereafter</li> <li>Age ≥7 years: every 5 years</li> </ul> </td> <td colspan="2" rowspan="3" style="vertical-align: middle;">MenB is not recommended unless it is otherwise indicated (eg, age 16 through 23 years based on shared decision-making).</td> </tr> <tr> <td class="indent1">Unvaccinated or undervaccinated college freshmen living in residence halls<sup>◊</sup></td> <td>1 dose of any MenACWY<sup>¶</sup></td> <td> <ul> <li>No recommendation unless otherwise indicated</li> </ul> </td> </tr> <tr> <td class="indent1">Unvaccinated or undervaccinated military recruits</td> <td>1 dose of any MenACWY<sup>¶</sup></td> <td> <ul> <li>Every 5 years depending on assignment<sup>§</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on meningococcal vaccination. Refer to UpToDate content for additional details, including meningococcal vaccination of persons at risk who are &lt;2 years of age, routine meningococcal vaccination of adolescents and young adults, and information about immunizations during meningococcal outbreaks. Some of the recommendations above are considered off-label (eg, administration of a 2-dose primary series for MenACWY, repeated booster doses of MenACWY or MenB).
    <ul class="decimal_heading">
<li>Two MenACWY are licensed in the United States:
            <ul>
<li>MenACWY-CRM (Menveo)</li>
<li>MenACWY-TT (MenQuadfi)</li>
</ul>
</li>
<li style="list-style-type: none;">MenACWY-D (Menactra) was discontinued in 2022.</li>
<li style="list-style-type: none;">Although each of the MenACWY vaccine formulations use a different protein conjugate, the products are considered interchangeable in persons ≥2 years of age. The same vaccine product is recommended, but not required, for all doses.</li>
<li>Two MenB vaccines are licensed in the United States:
            <ul>
<li>MenB-4C (Bexsero)</li>
<li>MenB-FHbp (Trumenba)</li>
</ul>
</li>
<li style="list-style-type: none;"><strong>MenB vaccines are not interchangeable</strong>; the same brand must be used for each dose of the primary series and all booster doses.</li>
</ul></div><div class="graphic_footnotes"><p>MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenB: serogroup B meningococcal vaccine; CDC: United States Centers for Disease Control and Prevention.</p>
<p>* Meningococcal vaccines should be administered ≥2 weeks before the first dose of complement inhibitor, unless the risk for delaying complement therapy outweighs the risk for developing meningococcal disease.</p>
<p>¶ Patients at increased risk of exposure who also have an immunodeficiency that increases the risk of meningococcal disease should receive the 2-dose primary series.</p>
<p>Δ Vaccination is recommended for international travelers visiting the parts of sub-Saharan Africa known as the meningitis belt during the dry season (December to June). The CDC issues advisories for other countries during epidemics of vaccine-preventable serogroups. Additional traveler's health information is available from the <a href="https://wwwnc.cdc.gov/travel" target="_blank">CDC</a>.</p>
<p>◊ College freshmen living in residence halls should receive ≥1 dose of MenACWY ≤5 years before college entry (preferably at age ≥16 years). If only 1 dose of vaccine was administered before the 16<sup>th</sup> birthday, a booster dose should be administered before enrollment.</p>
    
    § Vaccination recommendations for military personnel are made by the United States Department of Defense on the basis of high-risk travel requirements.</div><div class="graphic_reference">References:
    <ol>
<li>Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.</li>
<li>Immunization Action Coalition. Meningococcal ACWY vaccine recommendations by age and risk factor. <a href="https://www.immunize.org/catg.d/p2018.pdf" target="_blank">https://www.immunize.org/catg.d/p2018.pdf</a> (Accessed on October 26, 2020).</li>
<li>Immunization Action Coalition. Meningococcal B vaccine recommendations by age and risk factor. <a href="https://www.immunize.org/catg.d/p2035.pdf" target="_blank">https://www.immunize.org/catg.d/p2035.pdf</a> (Accessed on October 26, 2020).</li>
</ol></div><div id="graphicVersion">Graphic 130150 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
